Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization
2007

Multi-Antigen Vaccine Against Malaria in Rhesus Monkeys

Sample size: 20 publication 10 minutes Evidence: moderate

Author Information

Author(s): Jiang George, Charoenvit Yupin, Moreno Alberto, Baraceros Maria F, Banania Glenna, Richie Nancy, Abot Steve, Ganeshan Harini, Fallarme Victoria, Patterson Noelle B, Geall Andrew, Weiss Walter R, Strobert Elizabeth, Caro-Aquilar Ivette, Lanar David E, Saul Allan, Martin Laura B, Gowda Kalpana, Morrissette Craig R, Kaslow David C, Carucci Daniel J, Galinski Mary R, Doolan Denise L

Primary Institution: Naval Medical Research Center

Hypothesis

Can a multi-stage multi-immune response vaccine reduce malaria severity and mortality by targeting both liver and blood-stage antigens?

Conclusion

The study demonstrates that the CSLAM vaccine can induce robust immune responses in rhesus monkeys without antigen interference.

Supporting Evidence

  • All components of the multi-antigen mixture induced immune responses.
  • No antigen interference was observed in CSLAM compared to PfCSP alone.
  • CRL1005 formulation did not enhance T cell or antibody responses.
  • CD4+ T cell responses were more predominant than CD8+ responses.
  • PfAMA1 was the most immunogenic antigen in the study.
  • Responses were detected as early as 4 weeks after the first DNA immunization.
  • Immunogenicity was evaluated using ELIspot and ELISA assays.
  • Overall safety was maintained throughout the study.

Takeaway

Researchers tested a new malaria vaccine on monkeys and found it worked well without causing problems with the different parts of the vaccine getting in each other's way.

Methodology

Rhesus monkeys were immunized with DNA vaccines followed by a viral boost, and immune responses were measured using various assays.

Limitations

The effect of the CRL1005 formulation on immunogenicity was not significant, indicating potential limitations in enhancing vaccine efficacy.

Participant Demographics

Rhesus monkeys aged 5 to 10 years, weighing between 3 and 10 kg.

Statistical Information

P-Value

0.044

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1475-2875-6-135

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication